Year: 2025
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025
Denifanstat received Breakthrough Therapy designation from FDA for MASH
Clearance of Investigational New Drug (IND) application for FASN Inhibitor TVB-3567, to be developed for the treatment of acne
SAN MATEO, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2024, and provided recent corporate updates.
“2024 was a highly productive year for Sagimet, and we’re carrying that momentum into a strong start for 2025,” said David Happel, Chief Executive Officer of Sagimet. “We are pleased to have initiated...
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Q4 revenue of $32.3 million, increasing 14% year-over-year
Q4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%
Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.
For the Year EndedDecember 31,Key Performance Indicators (KPIs)*
2024
2023
(in thousands, except percentages)Average revenue per top 20 pharmaceutical manufacturer
$
2,933
$
2,399
Percent of top 20 pharmaceutical manufacturers that are customers
100
%
100
%Percent...
Foremost Clean Energy Announces $6.5 Million Uranium Exploration Program Across the Athabasca Basin
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) is pleased to announce its plans for a $6.5 million exploration program in 2025 (the “Program”) across its portfolio of uranium properties in the Athabasca Basin region in northern Saskatchewan. The Program includes the recently announced follow-up drill program on the Hatchet Lake Uranium Property (“Hatchet”) as well as planned exploration on the Murphy Lake South, GR, Blackwing, Wolverine, and CLK properties.
Following an initial evaluation of the exploration potential of the 10 properties under option from Denison Mines Corp. (“Denison”)(TSX: DML, NYSE: DNN), Foremost identified several exploration priorities for 2025. The extensive Program will include drilling, geophysical surveys,...
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
Written by Customer Service on . Posted in Public Companies.
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug
NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced upcoming scientific presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego, Calif., from April 5-9, 2025.
Oral presentations will focus on implementation of a validated research-use plasma...
Acuity Positioned for Growth and Compounding Value
Written by Customer Service on . Posted in Public Companies.
Rebrands and Introduces New Corporate Identity
ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) — Acuity Brands, Inc.’s (NYSE: AYI) corporate name is changing from Acuity Brands, Inc. to Acuity Inc. effective March 26, 2025. Acuity will continue to operate through two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), formerly Intelligent Spaces Group (ISG). We will continue trading on the New York Stock Exchange under the ticker symbol “AYI”.
“Acuity is positioned for long term growth. We are innovators, disruptors and builders who are creating stakeholder value and compounding shareholder wealth,” said Neil Ashe, Chief Executive Officer. “We are using technology to solve problems, redefine industries and create impactful experiences that shape how people live, work and connect.”
At Acuity, being an innovator...
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
Written by Customer Service on . Posted in Public Companies.
MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The live webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus...
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
Written by Customer Service on . Posted in Public Companies.
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus
ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models
BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has initiated a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease. The lead investigator of the trial is V. Koneti Rao, MD, FRCPA, Senior Research Physician, Primary Immune Deficiency Clinic (ALPS Clinic) at NIH Clinical...
Annual General Meeting 2025 – GN Store Nord A/S
Written by Customer Service on . Posted in Public Companies.
Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 17, 2025, as set out below.
The report by the Board of Directors was noted by the general meeting. The Annual Report 2024 and the proposal on distribution of annual profits, including no distribution of dividends, were approved, and discharge was granted to the Board of Directors and the Executive Management.
The general meeting approved the remuneration to the Board of Directors for 2025, and the 2024 Remuneration Report was approved in the advisory vote.
The proposal on the number of members of the Board of Directors was approved. Jukka Pekka Pertola, Klaus Holse, Hélène Barnekow, Jørgen Bundgaard Hansen and Kim Vejlby Hansen were re-elected to the Board of Directors by the general meeting....
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
Written by Customer Service on . Posted in Public Companies.
Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults.
AD begins with buildup of amyloid beta (Aβ) plaques and neurofibrillary tangles in the brain that causes brain cells to die over time and the brain to shrink.
The data demonstrate that initial deposition of Aβ triggers NLRP3 inflammasome activation causing release of ASC specks which rapidly enhance aggregation of Aβ. Aβ aggregates also activate NLRP3 inflammasomes thus triggering an ongoing cycle of IL-1β and ASC-mediated inflammation and Aβ deposition in the brain leading to AD progression. NLRP3 Inflammasome inhibition protected against development of AD pathology and neuroinflammation.
These data support the potential of ZyVersa’s Inflammasome ASC Inhibitor...
Stack Capital Group Inc. Reports 2024 Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
TORONTO, March 12, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK) today announced its financial results for the year ended December 31, 2024. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated.
Company Commentary:As at December 31, 2024, Book Value per Share (BVpS) of the Company was $12.29, compared with $11.05 as at September 30, 2024, an increase of 11.2%.
Stack Capital invested in a new portfolio company, CoreWeave, a leading AI hyper-scaler that provides GPU-accelerated infrastructure and solutions for businesses that require significant computational power such as those involved in AI, machine learning, scientific research, pixel streaming, visual effects rendering, and gaming applications. CoreWeave filed its S-1 on March 3, 2025, and is now preparing...